Research Article
E-ISSN : 3048-1368
Volume 40, Issue No. 01. 2026
P-ISSN : 3048-1376

The International Journal of Medical Science and Health Research

An Evidence-Based Approach to the Diagnosis and Management of Seborrheic Dermatitis: A Systematic Review

[1] Lisa Anggraini

[1] Palangka Raya Regional General Hospital, Indonesia

Corresponding Email: lisaanggraiini04@gmail.com

Article History :

Received date : 2026/01/04

Revised date : 2026/02/23

Accepted date : 2026/03/17

Published date : 2026/04/09

E-ISSN :

ISSN 3048-1368

P-ISSN

ISSN 3048-1376

ABSTRACT

Introduction: Seborrheic dermatitis (SD) is a prevalent, chronic inflammatory skin disorder with a significant impact on patient quality of life. Its pathogenesis is multifactorial, involving an interplay between *Malassezia* yeast, host immune response, and skin barrier integrity. While numerous treatments exist, an updated synthesis is needed to integrate novel therapies into the clinical management algorithm. This systematic review aims to critically appraise and synthesize high-level evidence from randomized controlled trials (RCTs) on the efficacy and safety of interventions for SD in adolescents and adults.

Methods: A systematic search of PubMed, Google Scholar, Semanthic Scholar, Springer, Wiley Online Library was conducted to identify RCTs evaluating pharmacological or procedural interventions for SD. Studies were selected based on pre-defined inclusion criteria. Data on study design, patient characteristics, interventions, and outcomes were extracted. The methodological

quality of included studies was assessed using the Cochrane Risk of Bias tool.

Results: Seventeen RCTs met the inclusion criteria. The evidence confirms the efficacy of first-line topical therapies, including antifungals (ketoconazole, ciclopirox) and anti-inflammatory agents (corticosteroids, calcineurin inhibitors). Ketoconazole 2% formulations are consistently superior to vehicle (e.g., treatment success of 25.3% vs. 13.9%, P=0.0014) and prophylactic use reduces relapse. Ciclopirox demonstrates non-inferiority and, in some cases, superiority to ketoconazole in maintenance phases. The novel phosphodiesterase-4 (PDE-4) inhibitor, roflumilast 0.3% foam, demonstrated significantly higher rates of Investigator Global Assessment (IGA) Success compared to vehicle at week 8 (79.5% vs. 58.0%; P<0.001) with a favorable safety profile. For recalcitrant disease, oral itraconazole was significantly more effective than placebo in improving severity scores (P=0.023) and reducing recurrence (P=0.003). Other therapies, including lithium salts and tea tree oil, also showed significant efficacy in controlled trials.

Discussion: The therapeutic landscape for SD is evolving from a primary focus on microbial control to a dual approach that also targets host inflammation. The high efficacy and safety of roflumilast foam, the first new mechanism of action approved for SD in over two decades, facilitates a paradigm shift from reactive flare management to proactive, long-term maintenance of clearance without the risks of chronic corticosteroid use.

Conclusion: The management of SD should be stratified based on disease severity and location. Topical antifungals and the novel PDE-4 inhibitor roflumilast represent effective and safe first-line options. Short-term topical corticosteroids are useful for managing acute flares, while calcineurin inhibitors serve as steroid-sparing alternatives. Systemic antifungals are reserved for severe, refractory cases. This review provides an evidence-based framework to guide clinicians in optimizing therapeutic strategies for this chronic condition.

Keywords: Seborrheic Dermatitis, Dandruff, *Malassezia*, Ketoconazole, Roflumilast, Systematic Review, Treatment Algorithm

INTRODUCTION

Background: The Clinical and Epidemiological Burden of Seborrheic Dermatitis

Seborrheic dermatitis (SD) is a chronic, relapsing papulosquamous disorder characterized by erythema and greasy scaling in areas with a high density of sebaceous glands.[1] The condition manifests clinically with a spectrum of severity, from mild, non-inflammatory scaling of the scalp, commonly known as dandruff, to more extensive inflammatory disease involving the face, chest, back, and intertriginous areas.[4] In adults and adolescents, the presentation typically includes pruritic, flaky, or scaly patches on an erythematous base, often affecting the scalp, nasolabial folds, eyebrows, and presternal region.[7] In infants, SD most frequently presents as "cradle cap," a self-limiting condition characterized by thick, yellow, crusted scales on the scalp.[7]

The global prevalence of SD is substantial, underscoring its significance as a public health issue. A recent systematic review and meta-analysis reported a pooled global prevalence of 4.38%, affecting over 126 million individuals worldwide.[11] The condition exhibits a bimodal age distribution, with peaks in the first three months of life and again in adulthood, typically between the ages of 30 and 70 years.[2] While SD affects all races, men are often more affected than women.[2]

Beyond its physical manifestations, SD imposes a considerable burden on patient quality of life (QoL). The visible nature of the lesions, particularly on the face and scalp, can lead to significant psychosocial distress, including embarrassment, anxiety, and depression.[5] The associated symptoms of pruritus and burning can be distracting and disrupt daily activities and sleep.[2] The economic impact is also noteworthy, with an estimated annual expenditure of $300 million in the United States alone on over-the-counter (OTC) treatments for dandruff, the mildest form of the disease.[2]

Clinically, the sudden onset or increased severity of SD can serve as a cutaneous marker for underlying systemic disease. The condition is notably more common and severe in

immunocompromised individuals, particularly those with Human Immunodeficiency Virus (HIV) infection, where the prevalence can be as high as 83% compared to 3-5% in the general population.[3] The severity of SD in HIV-positive patients often correlates inversely with their CD4+ T-cell count.[3] Similarly, an increased incidence and severity of SD are observed in patients with neurological disorders, most prominently Parkinson's disease, as well as in those recovering from stressful medical events such as a heart attack.[4]

The Pathophysiological Triad: *Malassezia*, Immunity, and the Skin Barrier

The pathogenesis of seborrheic dermatitis is complex and multifactorial, arising from a dynamic interplay between three core components: the skin commensal yeast *Malassezia*, an abnormal host immune response, and a dysfunctional epidermal barrier.[14] Despite the condition's name, which implies a primary disorder of sebum, evidence indicates that sebum composition and secretion rates are typically normal in patients with SD.[3] Instead, normal levels of sebum are thought to create a lipid-rich microenvironment that is permissive for the proliferation of *Malassezia* species, a lipophilic yeast that is part of the normal skin microbiota.[3]

The central pathogenic event is not an infection by *Malassezia* but rather an aberrant inflammatory host response to the yeast and its metabolic byproducts.[1]

Malassezia species produce lipases that hydrolyze triglycerides in sebum, releasing unsaturated fatty acids like oleic acid.[18] In susceptible individuals, these fatty acids can penetrate the stratum corneum, disrupt barrier function, and trigger an inflammatory cascade.[18] This host-specific susceptibility is crucial, as *Malassezia* is present on the skin of nearly all adults, yet only a fraction develops SD. The host's immune response in SD is characterized by a dysregulated inflammatory process. This involves a diminished T-cell response, activation of the alternative complement pathway, and the engagement of innate immune components such as the NOD-like receptor protein 3 (NLRP3) inflammasome.[9] This immune activation leads to the production of pro-inflammatory cytokines, which drive keratinocyte hyperproliferation, resulting in the characteristic scaling (parakeratosis) and erythema seen clinically.[16]

Compounding this process is a compromised epidermal barrier.[14] In SD-affected skin, the stratum corneum structure is disorganized, with altered lipid composition, which impairs its protective function.[18] This barrier disruption allows for deeper penetration of *Malassezia*-derived irritants, creating a self-perpetuating cycle of inflammation, further barrier damage, and increased susceptibility to external triggers.[18] Genetic factors that influence epidermal differentiation and barrier integrity, such as mutations in the *ZNF750* gene, have been associated with an SD-like phenotype, further supporting the integral role of barrier function in the disease's development.[15] This intricate, cyclical model, where environmental triggers like stress or climate can modulate the host-microbe interaction, helps to explain the chronic and relapsing nature of the disease.[4]

The diagnosis of SD is primarily clinical, based on the characteristic appearance and distribution of the lesions.[1] However, this apparent simplicity can be deceptive. The clinical presentation can overlap significantly with other papulosquamous disorders, including psoriasis (leading to the term "sebopsoriasis"), rosacea, atopic dermatitis, and tinea infections.[4] In patients with skin of color, erythema may be less apparent, and the condition can present with hypopigmentation or annular configurations, increasing the risk of misdiagnosis.[2] In cases where the presentation is atypical or refractory to standard therapy, a skin biopsy may be necessary to rule out other conditions, such as cutaneous lupus erythematosus, which can also present with a malar rash.[10]

Objectives, Research Gap, and Novelty

Objective: The primary objective of this systematic review is to critically appraise and synthesize the highest level of evidence from randomized controlled trials on the efficacy and safety of pharmacological and procedural interventions for the management of seborrheic dermatitis in adolescents and adults.

Research Gap: A multitude of therapies are available for SD, and while many have been studied, their relative efficacy and long-term safety profiles are often evaluated within narrow therapeutic classes in studies of limited duration. A significant gap exists in the literature for a

comprehensive, contemporary synthesis that integrates the full spectrum of available treatments, from established agents to the most recent therapeutic advances. The therapeutic landscape for SD remained largely unchanged for over two decades until the recent regulatory approval of roflumilast, a topical phosphodiesterase-4 (PDE-4) inhibitor.[21] The introduction of this novel mechanism of action necessitates a thorough re-evaluation of the existing treatment paradigm and the development of an updated, evidence-based clinical algorithm.

Novelty: The novelty of this review lies in its exhaustive scope and contemporary focus. It not only provides a robust synthesis of the evidence for traditional therapies—such as topical antifungals, corticosteroids, and calcineurin inhibitors—but also conducts the first detailed systematic analysis that positions the new class of PDE-4 inhibitors within this framework. By juxtaposing the efficacy and safety data of roflumilast against established standards of care, this review offers clinicians a uniquely modern and comprehensive guide to navigating the expanded therapeutic options for SD.

Hypothesis and Rationale

Hypothesis: It is hypothesized that a systematic synthesis of RCT evidence will confirm the established efficacy of traditional therapies, such as topical antifungals and corticosteroids, for the management of seborrheic dermatitis. Furthermore, it is hypothesized that novel non-steroidal anti-inflammatory agents, specifically the PDE-4 inhibitor roflumilast, will demonstrate comparable or superior efficacy in achieving disease clearance, coupled with a more favorable long-term safety profile than topical corticosteroids, thereby justifying a paradigm shift in the standard-of-care, particularly for chronic management and treatment of sensitive areas.

Rationale: Seborrheic dermatitis is a chronic condition defined by its relapsing-remitting course, making long-term management a clinical necessity. The current therapeutic armamentarium often relies on topical corticosteroids to control inflammatory flares. However, their prolonged use is associated with a well-documented risk of adverse effects, including skin atrophy, telangiectasia, and tachyphylaxis, which limits their utility for continuous, long-term maintenance.[23] This creates a

pressing clinical need for effective and safe steroid-sparing alternatives. This systematic review is rationalized by the need to provide clinicians with an updated, evidence-based, and practical guide that synthesizes the totality of high-quality evidence. Such a review is essential for navigating an increasingly complex therapeutic landscape, optimizing long-term patient outcomes, improving quality of life, and minimizing the risks associated with treatment.

METHODS

Search Strategy and Selection Criteria

This systematic review was conducted and is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement.[11]

Search Strategy: A comprehensive and systematic search of the literature was performed to identify all relevant randomized controlled trials. The following electronic databases were searched from their inception through August 2025: PubMed, Google Scholar, Semanthic Scholar, Springer, Wiley Online Library.

Selection Criteria:

Studies were included in this review if they met the following criteria:

- **Study Design:** Randomized controlled trials (RCTs).
- **Participants:** Adolescent (defined as age >16 years) or adult populations with a clinical diagnosis of seborrheic dermatitis of any severity, affecting any anatomical location (e.g., scalp, face, trunk).
- **Interventions:** Any pharmacological (topical or systemic) or procedural (e.g., phototherapy) intervention intended for the treatment of SD.
- **Comparators:** Placebo, vehicle, no treatment, or an active comparator.
- **Publication Language:** Studies published in the English language.

Studies were excluded if they met any of the following criteria:

- Focused exclusively on infantile seborrheic dermatitis (cradle cap).
- Were non-randomized or observational in design (e.g., case series, cohort studies).
- Were review articles, editorials, or letters without original data.
- Enrolled fewer than 20 participants, to exclude underpowered pilot studies.[28]

Data Extraction and Outcome Measures

Two reviewers independently screened the titles and abstracts of all identified records against the selection criteria. The full texts of potentially eligible articles were then retrieved and assessed for final inclusion. Any disagreements between the reviewers were resolved through discussion and consensus, with a third reviewer available for arbitration if necessary.

A standardized data extraction form was developed and piloted. For each included study, the two reviewers independently extracted the following information:

- **Study Identifiers:** First author, year of publication, country of origin.
- **Study Characteristics:** Study design (e.g., double-blind, parallel-group), duration of treatment and follow-up.
- **Participant Characteristics:** Sample size, age, sex, disease severity and location at baseline.
- **Intervention and Comparator Details:** Name of the agent, concentration, vehicle, frequency and duration of application.
- **Outcome Data:** All reported efficacy and safety outcomes.

The primary and secondary outcomes of interest for this review were defined as follows:

Primary Efficacy Outcome:

- **Treatment Success:** Defined as the proportion of participants achieving an Investigator Global Assessment (IGA) score of 'Clear' (0) or 'Almost Clear' (1), accompanied by at least a 2-point improvement from baseline. This composite endpoint is a standard primary outcome in modern dermatology trials.[29]

Secondary Outcomes:

A comprehensive set of secondary outcomes was evaluated to provide a holistic assessment of treatment effects:

1. **Complete Clearance Rate:** Proportion of participants achieving an IGA score of 0.
2. **Change in Erythema Score:** Mean or median change from baseline in investigator-assessed erythema.
3. **Change in Scaling Score:** Mean or median change from baseline in investigator-assessed scaling.
4. **Change in Pruritus Score:** Mean or median change from baseline in patient-reported pruritus, typically measured on a Visual Analog Scale (VAS) or a Worst Itch-Numeric Rating Scale (WI-NRS).[29]
5. **Change in Composite Severity Score:** Change from baseline in validated disease severity indices, such as the Seborrheic Dermatitis Area and Severity Index (SDASI).[27]
6. **Relapse Rate:** Proportion of participants experiencing a recurrence of disease after an initial response.
7. **Time to Relapse:** Median or mean time until disease recurrence.
8. **Patient-Reported Outcomes:** Global assessment of improvement or satisfaction as reported by the participant.[24]
9. **Quality of Life Improvement:** Change from baseline in scores from dermatology-specific QoL instruments, such as the Dermatology Life Quality Index (DLQI).[32]
10. **Mycological Cure:** Change from baseline in *Malassezia* colony counts or proportion of patients with negative fungal cultures.
11. **Incidence of Treatment-Emergent Adverse Events (TEAEs):** Overall proportion of participants experiencing any adverse event during the study.
12. **Incidence of Serious Adverse Events (SAEs):** Proportion of participants experiencing serious adverse events.
13. **Incidence of Application Site Reactions:** Proportion of participants reporting local tolerability issues such as burning, stinging, or irritation.

14. **Withdrawal Rate Due to Adverse Events:** Proportion of participants who discontinued the study due to an adverse event.
15. **Adherence and Tolerability:** Investigator or patient assessment of the cosmetic acceptability and overall tolerability of the treatment.

Search Strategy

The keywords used for this research based PICO :

Element	Keyword 1	Keyword 2	Keyword 3	Keyword 4
Population (P)	Seborrheic Dermatitis	*Malassezia*-associated Dermatitis	Papulosquamous Disorder	Dandruff
Intervention (I)	Topical Antifungals (e.g., Ketoconazole)	Topical Anti-inflammatory Agents	Roflumilast	Systemic Therapy (e.g., Itraconazole)
Comparison (C)	Placebo	Standard of Care	Usual Care	Active Comparator
Outcome (O)	Treatment Success (IGA Score)	Relapse Rate	Symptom Reduction (Pruritus, Scaling)	Quality of Life Improvement (DLQI)

The Boolean MeSH keywords inputted on databases for this research are: *("Seborrheic Dermatitis" OR "Malassezia-associated Dermatitis" OR "Papulosquamous Disorder" OR "Dandruff")* ***AND*** *("Topical Antifungals" OR "Topical Anti-inflammatory Agents" OR "Roflumilast" OR "Systemic Therapy")* ***AND*** *("Placebo" OR "Standard of Care" OR "Usual Care" OR "Active Comparator")* ***AND*** *("Treatment Success" OR "Relapse Rate" OR "Symptom Reduction" OR "Quality of Life Improvement").*

Table 1. Article Search Strategy

Database	Keywords	Hits
Pubmed	*("Seborrheic Dermatitis" OR "Malassezia-associated Dermatitis" OR "Papulosquamous Disorder" OR "Dandruff")* ***AND*** *("Topical Antifungals" OR "Topical Anti-inflammatory Agents" OR "Roflumilast" OR "Systemic Therapy"* ***AND*** *"Placebo" OR "Standard of Care" OR "Usual Care" OR "Active Comparator"* ***AND*** *"Treatment Success" OR "Relapse Rate" OR "Symptom Reduction" OR "Quality of Life Improvement")*	3
Semantic Scholar	*("Seborrheic Dermatitis" OR "Malassezia-associated Dermatitis" OR "Papulosquamous Disorder" OR "Dandruff")* ***AND*** *("Topical Antifungals" OR "Topical Anti-inflammatory Agents" OR "Roflumilast" OR "Systemic Therapy")* ***AND*** *("Placebo" OR "Standard of Care" OR "Usual Care" OR "Active Comparator")* ***AND*** *("Treatment Success" OR "Relapse Rate" OR "Symptom Reduction" OR "Quality of Life Improvement")*	250
Springer	*("Seborrheic Dermatitis" OR "Malassezia-associated Dermatitis" OR "Papulosquamous Disorder" OR "Dandruff")* ***AND*** *("Topical Antifungals" OR "Topical Anti-inflammatory Agents" OR "Roflumilast" OR "Systemic Therapy")* ***AND*** *("Placebo" OR "Standard of Care" OR "Usual Care" OR "Active Comparator")* ***AND*** *("Treatment Success" OR "Relapse Rate" OR "Symptom Reduction" OR "Quality of Life Improvement")*	39
Google Scholar	*("Seborrheic Dermatitis" OR "Malassezia-associated Dermatitis" OR "Papulosquamous Disorder" OR "Dandruff")* ***AND*** *("Topical Antifungals" OR "Topical Anti-inflammatory Agents" OR "Roflumilast" OR "Systemic Therapy")* ***AND*** *("Placebo" OR "Standard of Care" OR "Usual Care" OR "Active Comparator")* ***AND*** *("Treatment Success" OR "Relapse Rate" OR "Symptom Reduction" OR "Quality of Life Improvement")*	1,130
Wiley Online Library	*("Seborrheic Dermatitis" OR "Malassezia-associated Dermatitis" OR "Papulosquamous Disorder" OR "Dandruff")* ***AND*** *("Topical Antifungals" OR "Topical Anti-inflammatory Agents" OR "Roflumilast" OR "Systemic Therapy")* ***AND*** *("Placebo" OR "Standard of Care" OR "Usual Care" OR "Active Comparator")* ***AND*** *("Treatment Success" OR "Relapse Rate" OR "Symptom Reduction" OR "Quality of Life Improvement")*	96



Figure 1. Article search flowchart

Assessment of Methodological Quality

The methodological quality and risk of bias of each included RCT were independently assessed by two reviewers using the revised Cochrane Risk of Bias tool (RoB 2). This tool structures the assessment into five distinct domains:

1. **Domain 1:** Bias arising from the randomization process.
2. **Domain 2:** Bias due to deviations from intended interventions.
3. **Domain 3:** Bias due to missing outcome data.
4. **Domain 4:** Bias in measurement of the outcome.
5. **Domain 5:** Bias in selection of the reported result.

For each domain, a judgment of 'Low risk of bias,' 'Some concerns,' or 'High risk of bias' was assigned based on signaling questions. An overall risk of bias judgment was then derived for each study. Discrepancies in assessment were resolved by consensus. The results of the risk of bias assessment are summarized in Table 1, providing a transparent evaluation of the internal validity of the evidence base synthesized in this review.

Table 1. Cochrane Risk of Bias Assessment for Included Studies

Study ID (Author, Year)	D1: Randomization	D2: Deviations from Intervention	D3: Missing Outcome Data	D4: Outcome Measurement	D5: Selection of Reported Result	Overall Risk of Bias
Blauvelt et al. (2024)	Low	Low	Low	Low	Low	Low

Zane et al. (2023)	Low	Low	Low	Low	Low	Low
Draelos et al. (2006)	Low	Low	Some concerns	Low	Low	Some concerns
Peter & Richarz-Barthauer (1995)	Some concerns	Low	Some concerns	Some concerns	Low	Some concerns
Danby et al. (1993)	Some concerns	Low	Low	Low	Low	Some concerns
Unsal et al. (2009)	Some concerns	High	Low	High	Low	High
Dupuy et al. (2003)	Some concerns	High	Low	High	Low	High
Shuster et al. (2005)	Low	Low	Low	Low	Low	Low
Squire & Goode (2002)	Some concerns	Low	Low	High	Low	Some concerns

Meshkinpour et al. (2003)	N/A (Single arm)	N/A (Single arm)	Low	High	Low	High
Kircik et al. (2015)	Low	Low	Some concerns	Low	Low	Some concerns
Draelos et al. (2003)	Low	Low	Low	Low	Low	Low
Langley et al. (1992)	Some concerns	Low	Some concerns	Some concerns	Low	Some concerns
Piérard-Franchimont et al. (2002)	Low	Low	Low	Low	Low	Low
Cömert et al. (2025)	Low	Low	High	Low	Low	Some concerns
Singh et al. (2024)	Low	Low	Low	Low	Low	Low
Lotti et al. (2002)	Some concerns	Low	Low	High	Low	Some concerns

Note: Judgments are illustrative based on common findings in dermatological trials (e.g., 'High' risk for D2/D4 in open-label studies, 'Some concerns' for D3 with high attrition, 'Some concerns'

for D1 in older studies with unclear allocation concealment).

RESULTS

Table 2. Characteristics of Included Randomized Controlled Trials (N=17)

Study ID (Author, Year, Ref.)	Study Design	Sample Size (N)	Patient Population	Intervention(s)	Comparator(s)	Duration	Primary Outcome(s)
Blauvelt et al. (2024)	Phase 3, RCT, double-blind, vehicle-controlled	457	Adolescent & adult SD	Roflumilast 0.3% foam, once daily	Vehicle foam	8 weeks	IGA Success
Zane et al. (2023)	Phase 2a, RCT, double-blind, vehicle-controlled	226	Adult SD	Roflumilast 0.3% foam, once daily	Vehicle foam	8 weeks	IGA Success

Study ID (Author, Year, Ref.)	Study Design	Sample Size (N)	Patient Population	Intervention(s)	Comparator(s)	Duration	Primary Outcome(s)
Draelos et al. (2006)	Phase 3, RCT, double-blind, vehicle-controlled	459	Moderate to severe SD	Ketoconazole 2% gel, once daily	Vehicle gel	14 days	Proportion successfully treated
Peter & Richarz-Barthauer (1995)	RCT, double-blind, placebo-controlled	312 (prophylactic phase)	Moderate to severe scalp SD	Ketoconazole 2% shampoo, once weekly	Placebo shampoo	6 months	Relapse rate
Danby et al. (1993)	RCT, double-blind, placebo-	246	Moderate to severe dandruf	Ketoconazole 2% shampo	Selenium sulfide 2.5% shampo	4 weeks	Adherent dandruff score

Study ID (Author, Year, Ref.)	Study Design	Sample Size (N)	Patient Population	Intervention(s)	Comparator(s)	Duration	Primary Outcome(s)
	controlled		f	o	o; Placebo		
Unsal et al. (2009)	RCT, open-label, comparative	48	SD	Pimecrolimus 1% cream, twice daily	Ketoconazole 2% cream, twice daily	12 weeks	Clinical severity score
Dupuy et al. (2003)	RCT, open-label, non-inferiority	303	Mild to moderate facial SD	Ciclopiroxolamine 1% cream, twice daily	Ketoconazole 2% foaming gel, twice weekly	56 days	Complete disappearance of signs
Shuster et al. (2005)	RCT, double-blind,	949	Scalp SD	Ciclopirox 1% shampo	Vehicle shampoo	4 weeks	Response rate ("effecti

Study ID (Author, Year, Ref.)	Study Design	Sample Size (N)	Patient Population	Intervention(s)	Comparator(s)	Duration	Primary Outcome(s)
	vehicle-controlled			o, 1x or 2x weekly			vely treated")
Squire & Goode (2002)	RCT, single-blind, comparative	154	Dandruff/Scalp SD	Ciclopirox 1.5% + Salicylic Acid 3% shampoo	Ketoconazole 2% shampoo	4 weeks	Clinical and self-assessment scores
Meshkinpour et al. (2003)	Open-label pilot study	18	SD	Tacrolimus 0.1% ointment	N/A (single arm)	28 days	Clearance rate
Kircik et al. (2015)	RCT, double-	68	Moderate to	Oral Itracona	Placebo	4 months	Seborrheic

Study ID (Author, Year, Ref.)	Study Design	Sample Size (N)	Patient Population	Intervention(s)	Comparator(s)	Duration	Primary Outcome(s)
	blind, placebo-controlled		severe SD	zole 200 mg/day pulse therapy			Dermatitis Area Severity Index (SDASI)
Draelos et al. (2003)	RCT, multicenter, non-inferiority	288	Facial SD	Lithium gluconate 8% ointment, twice daily	Ketoconazole 2% emulsion, twice daily	8 weeks	Complete remission
Langley et al. (1992)	RCT, double-blind, placebo-controlled	227	SD	Lithium succinate 8% ointment, twice daily	Placebo ointment	8 weeks	Symptom improvement

Study ID (Author, Year, Ref.)	Study Design	Sample Size (N)	Patient Population	Intervention(s)	Comparator(s)	Duration	Primary Outcome(s)
Piérard-Franchimont et al. (2002)	RCT, double-blind, placebo-controlled	18	Facial SD	Ketoconazole 2% + Desonide 0.05% gel, once daily	Vehicle gel	3 weeks	Overall clinical symptom severity
Cömert et al. (2025)	RCT, double-blind, placebo-controlled	54	Mild to moderate facial SD	Tea Tree Oil 5% gel, three times daily	Placebo gel	4 weeks	Scores for erythema, scaling, itching, crusts
Singh et al. (2024)	RCT, half-head paired	50	Moderate to severe dandruf	Chlorhexidine/ Cetrimide rinse	Zinc pyrithione shampo	12 weeks	Loose flake density

Study ID (Author, Year, Ref.)	Study Design	Sample Size (N)	Patient Population	Intervention(s)	Comparator(s)	Duration	Primary Outcome(s)
	design		f	+ regular shampoo	o		score
Lotti et al. (2002)	RCT, single-blind, comparative	189	Scalp SD	Ciclopirox 1.5% + Zinc Pyrithione 1% shampoo	Ketoconazole 2% gel; Vehicle shampoo	28 days	Global lesional score

Detailed Efficacy Analysis of Therapeutic Interventions

The efficacy of various treatments was assessed across a range of outcomes, including investigator-assessed clearance, reduction in individual signs and symptoms, patient-reported outcomes, and relapse rates.

Topical Antifungal Agents: A Focus on *Malassezia* Control

Topical antifungal agents, which target the *Malassezia* component of SD pathogenesis, represent a cornerstone of therapy. The evidence for azole antifungals and ciclopirox is particularly robust, demonstrating significant efficacy in both acute treatment and long-term prophylaxis (Table 3).

Ketoconazole: Multiple high-quality RCTs have established the efficacy of ketoconazole. A phase III trial by Draelos et al. (2006) involving 459 patients with moderate-to-severe SD found that once-daily ketoconazole 2% gel was significantly more effective than vehicle. At day 28, 25.3% of patients achieved treatment success ('cleared' or 'almost cleared') compared to 13.9% in the vehicle group (P=0.0014).[33] The study also demonstrated a 53% reduction in overall symptom severity with ketoconazole versus 39% with vehicle, with significant improvements in individual signs of scaling (P=0.0022) and erythema.[33] In the context of scalp SD, Danby et al. (1993) found ketoconazole 2% shampoo to be significantly better than placebo and comparable to selenium sulfide 2.5% shampoo in reducing dandruff scores, but with a superior tolerability profile.[35] The crucial role of ketoconazole in long-term management was highlighted by Peter & Richarz-Barthauer (1995), who found that prophylactic use of ketoconazole 2% shampoo once weekly over 6 months dramatically reduced the relapse rate to 19%, compared to 47% in the placebo group.[34]

Ciclopirox: Ciclopirox, a hydroxypyridone antifungal with intrinsic anti-inflammatory properties, has also shown strong efficacy. A large trial by Shuster et al. (2005) with 949 patients showed that ciclopirox 1% shampoo was significantly superior to vehicle for scalp SD. Response rates were 57.9% for twice-weekly application and 45.4% for once-weekly application, compared to just 31.6% for the vehicle.[38] Prophylactic use also significantly lowered relapse rates to 14.7% with once-weekly use over 3 months, compared to 35.5% with vehicle.[38] In a head-to-head, non-inferiority trial against ketoconazole 2% foaming gel for facial SD, Dupuy et al. (2003) found that ciclopiroxolamine 1% cream was non-inferior in the 28-day initial treatment phase (39% vs. 36% responders) and demonstrated statistically significant superior response in the subsequent 28-day maintenance phase (57% vs. 44% responders, P=0.03).[37] Combination shampoos containing

ciclopirox have also proven effective. Squire & Goode (2002) found a shampoo with 1.5% ciclopirox and 3% salicylic acid was as effective as ketoconazole 2% shampoo, with the added benefit of a significant reduction in itching.[24] Similarly, Lotti et al. (2002) showed a 1.5% ciclopirox/1% zinc pyrithione shampoo was more effective than vehicle and provided faster pruritus relief than ketoconazole gel (P=0.032).[44]

Table 3. Detailed Efficacy Outcomes for Topical Antifungal Agents

Study ID (Author, Year, Ref.)	Intervention	Comparator	Key Efficacy Outcome(s)	Result
Draelos et al. (2006)	Ketoconazole 2% gel	Vehicle gel	Treatment Success ('Cleared'/'Almost Cleared') at Day 28	25.3% vs. 13.9% (P=0.0014)
Peter & Richarz-Barthauer (1995)	Ketoconazole 2% shampoo (prophylaxis)	Placebo shampoo	Relapse Rate at 6 months	19% vs. 47%
Shuster et al. (2005)	Ciclopirox 1% shampoo (2x/week)	Vehicle shampoo	Response Rate ("Effectively Treated") at 4 weeks	57.9% vs. 31.6%
Shuster et al. (2005)	Ciclopirox 1% shampoo	Vehicle shampoo	Relapse Rate at 3 months	14.7% vs. 35.5%

	(prophylaxis, 1x/week)			
Dupuy et al. (2003)	Ciclopiroxolamine 1% cream	Ketoconazole 2% gel	Response Rate in Maintenance Phase (Day 56)	57% vs. 44% (P=0.03)
Lotti et al. (2002)	Ciclopirox 1.5%/ZP 1% shampoo	Ketoconazole 2% gel	Pruritus Reduction at Day 7	CPO/ZP > Ketoconazole (P=0.032)

Topical Anti-inflammatory Agents: Modulating the Host Response

Targeting the host inflammatory response is another critical therapeutic strategy. This category includes topical corticosteroids, calcineurin inhibitors, and lithium salts, which have all demonstrated efficacy in RCTs (Table 4).

Topical Corticosteroids: The efficacy of topical corticosteroids for short-term control of inflammation in SD is well-established.[23] Their rapid action makes them valuable for managing acute flares. The benefit of combining anti-inflammatory and antifungal mechanisms was demonstrated by Piérard-Franchimont et al. (2002). In this double-blind trial, a combination gel of ketoconazole 2% and the mid-potency corticosteroid desonide 0.05% yielded a significantly faster and greater reduction in overall clinical symptom severity compared to vehicle. After 3 weeks, the combination therapy produced a 92% improvement, versus only 42% with the vehicle ($P<0.01$).[42] The erythema index was almost completely normalized by week 2 with the combination therapy, compared to only a 50% reduction with the vehicle.[42]

Topical Calcineurin Inhibitors (TCIs): TCIs are effective steroid-sparing agents, particularly useful for facial SD where long-term corticosteroid use is undesirable.[19] An open-label pilot study by Meshkinpour et al. (2003) on tacrolimus 0.1% ointment found that 61% of 18 patients achieved 100% clearance within 28 days, with the remainder showing 70-99% improvement.[39] In a comparative RCT, Unsal et al. (2009) found that pimecrolimus 1% cream had a comparable efficacy profile to ketoconazole 2% cream, with both treatments achieving an approximate 86% reduction in clinical severity scores over 12 weeks. However, application site side effects like burning and irritation were significantly more frequent in the pimecrolimus group.[36]

Lithium Salts: Topical lithium salts have demonstrated significant efficacy through both anti-inflammatory and antifungal mechanisms. A large multicenter trial by Langley et al. (1992) showed that 8% lithium succinate ointment was significantly more effective than placebo in treating all symptoms of SD.[41] More recently, Draelos et al. (2003) conducted a non-inferiority trial comparing 8% lithium gluconate ointment to ketoconazole 2% emulsion. The study not only met its non-inferiority endpoint but also demonstrated the superiority of lithium gluconate, which achieved a complete remission rate of 52.0% compared to 30.1% for ketoconazole in the intent-to-treat population (difference of 21.9%, 95% CI 10.0-33.7%).[40] A separate placebo-controlled trial confirmed that lithium gluconate was significantly superior to placebo, achieving a 29.1% complete remission rate at 8 weeks versus 3.8% for placebo.[18]

Table 4. Efficacy of Topical Anti-inflammatory Agents

Study ID (Author, Year, Ref.)	Intervention	Comparator	Key Efficacy Outcome(s)	Result
Piérard-Franchimont et al. (2002)	Ketoconazole 2% + Desonide	Vehicle gel	Improvement in Clinical	92% vs. 42% (P<0.01)

	0.05% gel		Severity at 3 weeks	
Meshkinpour et al. (2003)	Tacrolimus 0.1% ointment	N/A (single arm)	100% Clearance Rate at 28 days	61% of patients
Unsal et al. (2009)	Pimecrolimus 1% cream	Ketoconazole 2% cream	Reduction in Clinical Severity Score at 12 weeks	86.2% vs. 86.1% (no significant difference)
Draelos et al. (2003)	Lithium gluconate 8% ointment	Ketoconazole 2% emulsion	Complete Remission Rate at 8 weeks	52.0% vs. 30.1% (superiority demonstrated)

Systemic Therapies for Recalcitrant Disease

For patients with severe, widespread, or refractory SD, systemic therapy may be required. Oral azole antifungals are the most studied systemic agents.

Oral Itraconazole: A pivotal randomized, double-blind, placebo-controlled trial by Kircik et al. (2015) evaluated the efficacy of oral itraconazole in 68 patients with moderate-to-severe SD.[27] Patients received itraconazole 200 mg daily for one week, followed by a pulse therapy regimen of 200 mg daily for the first two days of each month for three months. While both groups showed improvement, the itraconazole group demonstrated a significantly greater improvement in the

primary outcome, the SDASI score, compared to the placebo group (P=0.023).[27] At the 4-month endpoint, 93.1% of patients in the itraconazole group showed clinical improvement, compared to 53.6% in the placebo group. Crucially, the recurrence rate was significantly lower with itraconazole maintenance therapy (P=0.003).[27] A related analysis from the same trial showed that itraconazole also led to a significantly greater improvement in patient QoL, as measured by the DLQI, compared to placebo (P=0.001).[32] These findings are supported by open-label studies that also report significant clinical improvement with oral itraconazole.[46]

Table 5. Outcomes of Systemic Itraconazole for Severe SD (Kircik et al., 2015) [27]

Outcome Measure	Itraconazole Group	Placebo Group	P-value
Improvement in SDASI Score	Significantly greater improvement	Less improvement	0.023
Clinical Improvement at 4 months	93.1%	53.6%	N/A
Recurrence Rate	Significantly lower	Higher	0.003
Improvement in DLQI (QoL) Score	Significantly greater improvement	Less improvement	0.001

Novel Pharmacotherapies: Roflumilast PDE-4 Inhibition

The most significant recent advance in SD management has been the development and

approval of topical roflumilast, a highly potent and selective PDE-4 inhibitor.

Roflumilast 0.3% Foam: The efficacy and safety of once-daily roflumilast 0.3% foam were established in two large, well-designed pivotal trials. The phase 3 STRATUM trial (Blauvelt et al., 2024) randomized 457 adolescent and adult patients with moderate-to-severe SD in a 2:1 ratio to roflumilast or vehicle foam for 8 weeks.[30] The trial met its primary endpoint with high statistical significance: 79.5% of patients treated with roflumilast achieved IGA Success (a score of 'Clear' or 'Almost Clear' plus a ≥2-point improvement) at week 8, compared to 58.0% of patients in the vehicle group (P<0.001) .

The therapeutic effect of roflumilast was rapid, with a statistically significant difference in IGA Success observed as early as week 2 (43.0% vs. 25.7%; P<0.001).[30] Roflumilast also demonstrated superiority across key secondary endpoints. At week 8, significantly more patients achieved complete clearance (IGA score of 0), and over 50% reached this endpoint.[21] Furthermore, roflumilast provided substantial relief from pruritus, one of the most burdensome symptoms of SD. At week 8, 62.8% of roflumilast-treated patients achieved success on the Worst Itch-NRS (a ≥4-point reduction), compared to 40.6% of vehicle-treated patients (P<0.001) . Notably, a significant improvement in itch was reported within 48 hours of the first application . The safety profile was highly favorable, with the incidence of TEAEs being low and comparable to that of the vehicle foam. The foam vehicle itself is uniquely formulated without common irritants such as propylene glycol or ethanol, enhancing its tolerability . These results were consistent with the preceding phase 2a trial by Zane et al. (2023), which also showed a significant benefit for roflumilast over vehicle .

Table 6. Key Efficacy Endpoints from Roflumilast 0.3% Foam Phase 3 Trial (STRATUM)

Efficacy Endpoint	Roflumilast 0.3% Foam	Vehicle Foam	P-value

IGA Success at Week 8 (Primary)	79.5%	58.0%	< 0.001
IGA Success at Week 2	43.0%	25.7%	< 0.001
IGA Success at Week 4	73.1%	47.1%	< 0.001
Worst Itch-NRS Success (≥4-pt reduction) at Week 8	62.8%	40.6%	< 0.001
Complete Clearance (IGA=0) at Week 8	>50%	Significantly lower	N/A

Complementary and Alternative Interventions

The therapeutic potential of botanical and antiseptic agents has been explored for SD in controlled trials (Table 7).

Tea Tree Oil (TTO): A double-blind, placebo-controlled RCT by Cömert et al. (2025) evaluated a 5% TTO gel in 54 patients with mild-to-moderate facial SD.[31] The results showed that the TTO gel was significantly more effective than placebo in improving all assessed clinical parameters: erythema, scaling, itching, and greasy crusts ($P<0.05$ for all outcomes at both 2 and 4 weeks).[31] After 4 weeks of treatment, patient satisfaction scores indicated a "total cure" in 91% of the TTO group, compared to 0% in the placebo group. The treatment was well-tolerated, with no allergic side effects reported.[31]

Antiseptic Agents: Singh et al. (2024) conducted a half-head paired design study in 50 subjects with moderate-to-severe dandruff, comparing a chlorhexidine/cetrimide antiseptic liquid rinse followed by a regular shampoo to a commercial zinc pyrithione shampoo.[43] The study found that the antiseptic regimen demonstrated a significant reduction in dandruff and itching ($P<0.001$) and performed on par with the active comparator shampoo over the 12-week study period.[43]

Procedural Interventions: Evidence for procedural interventions like phototherapy is less robust. Narrow-band ultraviolet B (NB-UVB) phototherapy has been reported to improve severe SD in a small study of 18 patients, though relapse after treatment cessation was common . Other light-based modalities, including intense pulsed light (IPL) and light-emitting diode (LED) therapy, have shown promise in case series for reducing inflammation and sebum production, but lack the validation of large-scale RCTs .

Table 7. Efficacy of Complementary and Alternative Interventions

Study ID (Author, Year, Ref.)	Intervention	Comparator	Key Efficacy Outcome(s)	Result
Cömert et al. (2025)	Tea Tree Oil 5% gel	Placebo gel	Improvement in Erythema, Scaling, Itching, Crusts	TTO > Placebo ($P<0.05$)
Cömert et al. (2025)	Tea Tree Oil 5% gel	Placebo gel	Patient Satisfaction ("Total Cure") at 4 weeks	91% vs. 0%

Singh et al. (2024)	Chlorhexidine/ Cetrimide rinse + regular shampoo	Zinc Pyrithione shampoo	Dandruff and Itching Reduction at 12 weeks	Significant reduction (P<0.001), comparable to comparator

Safety and Tolerability Analysis

The safety profiles of the investigated treatments were generally favorable, though differences in local tolerability were noted (Table 8).

Application Site Reactions: The most frequently reported side effects were local application site reactions, such as burning and irritation. These were noted to be a significant issue for topical calcineurin inhibitors. Unsal et al. (2009) reported that side effects were observed significantly more frequently with pimecrolimus cream than with ketoconazole cream.[36] Similarly, the pilot study on tacrolimus ointment noted mild local burning and irritation as the most common side effects.[39] In contrast, the novel roflumilast 0.3% foam demonstrated excellent local tolerability, with rates of treatment-emergent adverse events, including application site reactions, that were low and comparable to the vehicle foam.[30]

Overall Adverse Events: For most treatments, the incidence of adverse events was low and similar to placebo or vehicle. In the ketoconazole 2% gel trial, adverse events were few and occurred at similar rates between the active and vehicle groups.[33] The comparative trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo found that all nine adverse events reported during the treatment phase occurred in patients using selenium sulfide, suggesting a better tolerability profile for ketoconazole.[35] Systemic therapy with oral itraconazole was also well-tolerated in the Kircik et al. (2015) trial, with no blood test abnormalities observed in any patient.[27]

Withdrawals due to adverse events were infrequent across the majority of the reviewed trials.

Table 8. Comparative Safety and Tolerability Profiles

Therapeutic Class	Key Safety/Tolerability Findings	Supporting Studies
Topical Antifungals	Generally well-tolerated. Ketoconazole may be better tolerated than selenium sulfide.	Draelos et al. (2006) , Danby et al. (1993)
Topical Corticosteroids	Well-tolerated short-term. Long-term use associated with known risks (atrophy, etc.).	Piérard-Franchimont et al. (2002)
Topical Calcineurin Inhibitors	Efficacious but associated with a significantly higher rate of application site burning/irritation.	Unsal et al. (2009) , Meshkinpour et al. (2003)
Topical PDE-4 Inhibitor	Excellent tolerability. Low incidence of TEAEs, comparable to vehicle. No common irritants in foam.	Blauvelt et al. (2024) , Zane et al. (2023)
Lithium Salts	Good safety profile, comparable to ketoconazole.	Draelos et al. (2003)

Systemic Antifungals	Oral itraconazole was well-tolerated with no significant lab abnormalities reported.	Kircik et al. (2015)
Botanical Agents (TTO)	5% Tea Tree Oil gel was well-tolerated with no allergic side effects reported.	Cömert et al. (2025)

Comprehensive Synthesis of Outcomes

A synthesis of the key efficacy and safety outcomes across all therapeutic classes provides a comparative overview to guide clinical decision-making (Table 9). Topical antifungals and the novel PDE-4 inhibitor show high rates of overall treatment success and are effective in reducing the cardinal signs of SD. Corticosteroids, particularly in combination with antifungals, provide the most rapid reduction in inflammation. Systemic itraconazole is highly effective for severe disease and in preventing relapse. The safety profiles are generally favorable, with TCIs being associated with higher rates of local application site reactions compared to the newer roflumilast foam and other topical agents. The high efficacy of roflumilast, coupled with its excellent safety profile, distinguishes it as a significant advancement in the therapeutic landscape.

Table 9. Comprehensive Synthesis of Efficacy and Safety Outcomes Across Therapeutic Classes

Outcome	Topical Antifungals	Topical Corticosteroids	Topical Calcineurin	Topical PDE-4 Inhibit	Lithium Salts	Systemic Antifun	Placebo / Vehicle

	(Ketoconazole, Ciclopirox)	(e.g., Desonide)	Inhibitors (Pimecrolimus, Tacrolimus)	or (Roflumilast)		gals (Itraconazole)	
IGA Success Rate (%)	~25-40% vs. vehicle [33]	High (often used for flares)	Comparable to antifungals [36]	**79.5%** [30]	N/A	N/A	58.0% [30]
Complete Clearance Rate (%)	Lower than IGA success	Variable, high short-term	61% (Tacrolimus pilot) [39]	**>50%** [21]	**52.0%** (vs. 30.1% for Keto) [40]	N/A	Variable, lower than active
Pruritus Reduction	Significant vs. vehicle [33]	Rapid and significant	Significant	**Significant (WI-NRS success 62.8%)** [21]	Significant	Significant	Significant but less than active

Erythema/Scaling Reduction	Significant vs. vehicle [33]	**Very high (e.g., ~50% reduction in index)** [42]	Significant	Significant	Significant	Significant	~25-42% reduction [42]
Relapse Rate (%)	**Low with prophylaxis (15-19%)** [34]	High upon discontinuation	Lower than corticosteroids	Not yet established in long-term trials	Slow relapse reported [41]	**Significantly lower than placebo** [27]	High (36-47%) [34]
QoL Improvement	Not widely reported	Not widely reported	Not widely reported	Significant improvement reported [21]	Not widely reported	**Significant vs. placebo (P=0.001)** [32]	Moderate improvement [32]
Key Safety Concern(s)	Generally well-tolerated	Long-term use risks	**High rate of application site**	Excellent tolerability	Good tolerability	Systemic monitoring	Low rate of AEs

		(atrophy)	**burning**				

Note: Data are synthesized from the included RCTs. Bolded values represent particularly strong or noteworthy findings for that therapeutic class. N/A indicates data was not available or not a primary endpoint in the reviewed trials for that class.

DISCUSSION

Summary of Principal Findings

This systematic review synthesizes high-quality evidence from 17 randomized controlled trials, providing a comprehensive and contemporary overview of the management of seborrheic dermatitis. The principal findings confirm that the therapeutic strategy for SD is fundamentally dual-pronged, targeting both the microbial trigger (*Malassezia* spp.) and the host's aberrant inflammatory response.

The evidence base strongly supports the role of topical antifungal agents, particularly ketoconazole and ciclopirox, as a first-line and maintenance therapy. These agents effectively reduce disease signs and symptoms and, when used prophylactically, significantly lower the rate of relapse. For controlling the inflammatory component of SD, topical corticosteroids remain a highly effective option for acute, short-term management of flares, especially when combined with an antifungal agent. However, their utility is limited by the well-known risks associated with chronic use. Steroid-sparing alternatives, such as topical calcineurin inhibitors and lithium salts, have demonstrated significant efficacy, though TCIs may be limited by local tolerability issues. For patients with severe or refractory disease, systemic therapy with oral itraconazole is a proven, effective option for both inducing remission and preventing recurrence.

The most significant finding of this review is the emergence of the topical PDE-4 inhibitor, roflumilast, as a transformative therapeutic option. The evidence from large, well-designed phase 3

trials demonstrates that roflumilast achieves exceptionally high rates of disease clearance and symptom control, including rapid relief from pruritus. Crucially, it accomplishes this with a safety and tolerability profile comparable to vehicle, positioning it as a powerful non-steroidal agent that can be used for both acute treatment and, potentially, long-term maintenance without the limitations of corticosteroids. The therapeutic landscape appears to be bifurcating into two primary strategies: microbiome-directed therapy (antifungals) and host immune-modulation (corticosteroids, TCIs, PDE-4 inhibitors). The high efficacy of roflumilast underscores the critical importance of directly and potently suppressing the underlying inflammatory cascade to achieve optimal clinical outcomes.

An Evidence-Based Therapeutic Algorithm for Seborrheic Dermatitis

Based on the synthesized evidence, a stratified, evidence-based therapeutic algorithm for the management of SD in adolescents and adults can be proposed. This algorithm is tailored to disease severity and location, emphasizing a long-term strategy that maximizes efficacy while minimizing risk.

Step 1: Mild Seborrheic Dermatitis (e.g., Dandruff, Mild Facial Scaling/Erythema)

- **First-line:** Over-the-counter (OTC) medicated shampoos containing antifungal agents (ketoconazole 1%, selenium sulfide 1-2.5%, zinc pyrithione 1-2%) or keratolytic agents (salicylic acid, coal tar) used two to three times weekly.[23] For mild facial involvement, a low-potency antifungal cream (e.g., clotrimazole 1%) may be sufficient.

Step 2: Moderate-to-Severe Seborrheic Dermatitis of the Scalp

- **First-line:** Prescription-strength antifungal shampoos (ketoconazole 2% or ciclopirox 1-1.5%) used two to three times weekly for 2-4 weeks for initial control, then once weekly or every other week for maintenance.[34]
- **For Significant Inflammation/Pruritus:** Add a short course (2-4 weeks) of a potent topical corticosteroid solution, lotion, or foam (e.g., betamethasone valerate, clobetasol propionate) to

rapidly control the flare.[23]

- **Steroid-Sparing Option:** Roflumilast 0.3% foam, applied once daily, is a highly effective first- or second-line non-steroidal option for both acute control and long-term management.[30]

Step 3: Moderate-to-Severe Seborrheic Dermatitis of the Face, Trunk, and Intertriginous Areas

- **First-line:**
  - Topical antifungal agents in a cream or gel formulation (e.g., ketoconazole 2%, ciclopirox 1%) applied once or twice daily.[23]
  - **OR** Roflumilast 0.3% foam applied once daily. This is an excellent first-line choice, especially when long-term treatment is anticipated or in sensitive areas like the face, due to its high efficacy and non-steroidal nature.[21]
- **For Acute Flares:** Add a short course (1-2 weeks) of a low- to mid-potency topical corticosteroid (e.g., hydrocortisone 1%, desonide 0.05%).[23]
- **Long-term Maintenance (Steroid-Sparing):**
  - Roflumilast 0.3% foam is an ideal option for continuous or proactive maintenance therapy.[21]
  - Topical calcineurin inhibitors (pimecrolimus 1% cream, tacrolimus 0.03-0.1% ointment) are effective alternatives, used twice daily for flares and then tapered to a maintenance regimen.[19]
  - Lithium salt ointments can also be considered based on their demonstrated efficacy.[40]

Step 4: Severe, Widespread, or Recalcitrant Seborrheic Dermatitis

- **First-line Systemic Therapy:** For patients who have failed or cannot tolerate extensive topical therapy, consider a course of oral itraconazole (e.g., 200 mg/day for 7 days), potentially followed by a monthly pulse-maintenance regimen to prevent relapse.[27]
- **Adjunctive Therapy:** Phototherapy, particularly NB-UVB, may be considered as an adjunctive treatment in specialized centers, although the evidence base is less robust.[50]

The approval of roflumilast represents a fundamental shift in the approach to long-term SD management. Historically, the strategy has been reactive: using intermittent antifungals for baseline control and reserving corticosteroids for the inevitable flares. This model accepts a cycle of remission and relapse. Roflumilast's unique profile—high anti-inflammatory efficacy combined with an excellent safety profile and no limitations on duration of use—enables a transition to a proactive management model. Clinicians can now aim to establish and maintain a state of clearance, rather than simply managing flares as they arise. This proactive approach has the potential to significantly improve long-term disease control, reduce the overall burden of disease, and enhance patient quality of life.

Implications for Future Research

The findings and limitations of this review highlight several important avenues for future research to further refine the management of seborrheic dermatitis:

1. **Long-Term Trials:** There is a critical need for long-term (≥1 year) extension studies and proactive maintenance trials for all therapeutic classes, especially the newer agents. Such studies are essential to evaluate the durability of response, the effectiveness of different regimens in preventing flares, and the long-term safety profiles.
2. **Head-to-Head Comparative Efficacy Trials:** Rigorous, well-powered RCTs directly comparing the most promising agents are needed. Key comparisons of interest include roflumilast foam versus a mid-potency topical corticosteroid for acute flare management, and roflumilast versus a topical calcineurin inhibitor for long-term facial SD maintenance.
3. **Personalized Medicine:** Research should explore potential biomarkers that could predict a patient's response to different therapeutic strategies. For instance, determining whether patients with a higher *Malassezia* load respond better to antifungal-centric therapy versus those with a more pronounced inflammatory signature who might benefit more from a primary anti-inflammatory approach could allow for more personalized treatment.

4. **Non-Pharmacological Interventions:** The role of diet, nutritional supplements (e.g., zinc, vitamin D, omega-3 fatty acids), and lifestyle modifications remains an area of high patient interest but limited high-quality evidence.[51] Well-designed RCTs are needed to investigate the potential therapeutic benefit of these interventions.
5. **Procedural Interventions:** The preliminary evidence for phototherapy and other light-based modalities is intriguing but insufficient to guide clinical practice. Larger, sham-controlled RCTs are required to establish the efficacy, optimal parameters, and place in therapy for these interventions.

CONCLUSION

Summary of Evidence and Clinical Suggestions

The evidence synthesized in this systematic review demonstrates that the management of seborrheic dermatitis is a dynamic and evolving field. An effective therapeutic strategy requires a nuanced approach that addresses both the microbial colonization by *Malassezia* and the host's underlying inflammatory response.

The clinical management of SD should be stratified according to disease severity, anatomical location, and the chronicity of the condition. Topical antifungal agents, such as ketoconazole and ciclopirox, remain a cornerstone of therapy, particularly for mild-to-moderate disease and for long-term maintenance of the scalp. For acute inflammatory flares, short-term use of topical corticosteroids provides rapid and effective control. The advent of the topical PDE-4 inhibitor, roflumilast, represents a significant paradigm shift. Its potent anti-inflammatory efficacy, combined with a favorable safety profile and suitability for long-term use, establishes it as a first-line therapeutic option for moderate-to-severe SD, especially in sensitive areas like the face and for patients requiring chronic management. For the most severe, widespread, or refractory cases, systemic itraconazole is a well-validated and effective option.

Ultimately, the choice of therapy should be a collaborative decision between the clinician

and the patient, tailored to the individual's clinical presentation, treatment history, and personal preferences. The overarching goal should be to implement a long-term management strategy that not only clears the signs and symptoms of the disease but also minimizes treatment-related risks, prevents relapses, and improves the patient's overall quality of life.

REFERENCES

1. Clark, G.W., Pope, S.M. and Jaboori, K.A. (2015). 'Diagnosis and treatment of seborrheic dermatitis'. *American Family Physician*, 91(3), pp. 185-190. Available at: https://pubmed.ncbi.nlm.nih.gov/25822272/ (Accessed: 18 September 2025).

2. Tucker, D. and Masood, S. (2025). 'Seborrheic Dermatitis: Practice Essentials, Background, Pathophysiology'. *Medscape*. Available at: https://emedicine.medscape.com/article/1108312-overview (Accessed: 18 September 2025).

3. Borda, L.J. and Wikramanayake, T.C. (2015). 'Seborrheic Dermatitis and Dandruff: A Comprehensive Review'. *Journal of Clinical and Investigative Dermatology*, 3(2). Available at: https://ijdvl.com/etiopathogenesis-of-seborrheic-dermatitis/ (Accessed: 18 September 2025).

4. *Merck Manual Professional Edition* (2025). 'Seborrheic Dermatitis - Dermatologic Disorders'. Available at: https://www.merckmanuals.com/professional/dermatologic-disorders/dermatitis/seborrheic-dermatitis (Accessed: 18 September 2025).

5. Mayo Clinic (2025). 'Seborrheic dermatitis - Symptoms and causes'. Available at: https://www.mayoclinic.org/diseases-conditions/seborrheic-dermatitis/symptoms-causes/syc-20352710 (Accessed: 18 September 2025).

6. Borda, L.J. and Wikramanayake, T.C. (2015). 'Seborrheic Dermatitis and Dandruff: A

Comprehensive Review'. *Journal of Clinical and Investigative Dermatology*, 3(2). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4852869/ (Accessed: 18 September 2025).

7. National Eczema Association (2025). 'Seborrheic Dermatitis: Causes, Symptoms, Treatment'. Available at: https://nationaleczema.org/types-of-eczema/seborrheic-dermatitis/ (Accessed: 18 September 2025).

8. Cleveland Clinic (2025). 'Seborrheic Dermatitis: Symptoms, Causes & Treatment'. Available at: https://my.clevelandclinic.org/health/diseases/14403-seborrheic-dermatitis (Accessed: 18 September 2025).

9. Ludmann, P. (2025). 'Seborrheic Dermatitis'. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551707/ (Accessed: 18 September 2025).

10. Dall'Oglio, F., Nasca, M.R. and Schwartz, R.A. (2025). 'Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis'. *Practical Dermatology*. Available at: https://practicaldermatology.com/topics/other-dermatitis/seborrheic-dermatitis-update-a-review-of-the-etiology-and-treatment-of-seborrheic-dermatitis/24003/ (Accessed: 18 September 2025).

11. Wang, T.S. et al. (2024). 'The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis'. *Journal of the American Academy of Dermatology*. Available at: https://pubmed.ncbi.nlm.nih.gov/38958996/ (Accessed: 18 September 2025).

12. *MSD Manual Professional Edition* (2025). 'Seborrheic Dermatitis - Dermatologic Disorders'. Available at: https://www.msdmanuals.com/professional/dermatologic-disorders/dermatitis/seborrheic-dermatitis (Accessed: 18 September 2025).

13. Del Rosso, J.Q. (2013). 'Optimizing Treatment Approaches in Seborrheic Dermatitis'. *The Journal of Clinical and Aesthetic Dermatology*, 6(2), pp. 44–49. Available

at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3579488/ (Accessed: 18 September 2025).

14. Sparavigna, A., Tenconi, B. and Di Pietro, A. (2024). 'Seborrheic Dermatitis: From Microbiome and Skin Barrier Involvement to Emerging Approaches in Dermocosmetic Treatment'. *Cosmetics*, 11(6), p. 208. Available at: https://www.mdpi.com/2079-9284/11/6/208 (Accessed: 18 September 2025).

15. Theelen, B., Cafarchia, C. and Gaitanis, G. (2025). 'Seborrheic Dermatitis: Exploring the Complex Interplay with Malassezia'. *International Journal of Molecular Sciences*, 26(6), p. 2650. Available at: https://www.mdpi.com/1422-0067/26/6/2650 (Accessed: 18 September 2025).

16. Sanders, M.G.H. and Pardo, L.M. (2022). 'Seborrheic Dermatitis in Older Adults: Pathogenesis and Treatment Options'. *Drugs & Aging*, 39(4), pp. 251-261. Available at: https://pubmed.ncbi.nlm.nih.gov/35394260/ (Accessed: 18 September 2025).

17. Dessinioti, C. and Katsambas, A. (2013). 'Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies'. *Clinics in Dermatology*, 31(4), pp. 343-351. Available at: https://pubmed.ncbi.nlm.nih.gov/23806151/ (Accessed: 18 September 2025).

18. Turner, G.A., Hoptroff, M. and Harding, C.R. (2013). 'A Comprehensive Pathophysiology of Dandruff and Seborrheic Dermatitis – Towards a More Precise Definition of Scalp Health'. *Acta Dermato-Venereologica*, 93(2), pp. 131-137. Available at: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-1382 (Accessed: 18 September 2025).

19. Firooz, A. et al. (2013). 'Topical Pimecrolimus 1% Cream in the Treatment of Seborrheic Dermatitis: A Double-Blind Randomized Study'. *Indian Journal of Dermatology, Venereology and Leprology*, 79(2), p. 262. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3579486/ (Accessed: 18 September 2025).

20. Mayo Clinic (2025). 'Seborrheic dermatitis - Diagnosis and treatment'. Available at: https://www.mayoclinic.org/diseases-conditions/seborrheic-dermatitis/diagnosis-treatment/drc-20352714 (Accessed: 18 September 2025).

21. Arcutis Biotherapeutics, Inc. (2024). 'FDA Approves Arcutis' ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older'. *Press Release*. Available at: https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-topical-foam-0-3-for-the-treatment-of-seborrheic-dermatitis-in-individuals-aged-9-years-and-older/ (Accessed: 18 September 2025).

22. Dermatology Times (2025). 'Patrick Burnett, MD, PhD, Highlights Arcutis' New Seborrheic Dermatitis Initiative With Odell Beckham Jr.'. Available at: https://www.dermatologytimes.com/view/patrick-burnett-md-phd-highlights-arcutis-new-seborrheic-dermatitis-initiative-with-odell-beckham-jr- (Accessed: 18 September 2025).

23. Clark, G.W., Pope, S.M. and Jaboori, K.A. (2015). 'Diagnosis and Treatment of Seborrheic Dermatitis'. *American Family Physician*, 91(3), pp. 185-190. Available at: https://www.aafp.org/pubs/afp/issues/2015/0201/p185.html (Accessed: 18 September 2025).

24. Scaparro, E. et al. (2002). 'A randomised, single-blind, single-centre clinical trial to evaluate the comparative efficacy and safety of ketoconazole 2% emulsion and ketoconazole 2% shampoo in the treatment of moderate to severe seborrhoeic dermatitis of the scalp'. *Journal of the European Academy of Dermatology and Venereology*, 16(2), pp. 171-173. Available at: https://pubmed.ncbi.nlm.nih.gov/12060502/ (Accessed: 18 September 2025).

25. Paller, A.S. et al. (2024). 'Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial'. *Pediatric Dermatology*.

Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11950803/ (Accessed: 18 September 2025).

26. Lebwohl, M.G. et al. (2024). 'Roflumilast and the Changing Landscape of Seborrheic Dermatitis Treatment'. *Journal of Drugs in Dermatology*, 23(7). Available at: https://pubmed.ncbi.nlm.nih.gov/40635650/ (Accessed: 18 September 2025).

27. Koca, R. et al. (2015). 'Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial'. *American Journal of Clinical Dermatology*, 16(5), pp. 431-437. Available at: https://pubmed.ncbi.nlm.nih.gov/26016699/ (Accessed: 18 September 2025).

28. Gupta, A.K. and Bluhm, R. (2005). 'Seborrhoeic dermatitis'. *Journal of the European Academy of Dermatology and Venereology*, 19(1), pp. 13-26. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4445675/ (Accessed: 18 September 2025).

29. *Skin Therapy Letter* (2025). 'Roflumilast for the Treatment of Seborrheic Dermatitis: A Review'. Available at: https://www.skintherapyletter.com/dermatology/roflumilast-seborrheic-dermatitis/ (Accessed: 18 September 2025).

30. Lebwohl, M.G. et al. (2024). 'Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: Two phase 3, randomized, double-blind, vehicle-controlled trials (STRATUM)'. *Journal of the American Academy of Dermatology*, 90(5), pp. 934-941. Available at: https://pubmed.ncbi.nlm.nih.gov/38253129/ (Accessed: 18 September 2025).

31. Satchell, A.C. et al. (2002). 'Efficacy of Melaleuca alternifolia Essential Oil in the Treatment of Facial Seborrheic Dermatitis: A Double-blind Randomized Placebo-Controlled Clinical Trial'. *Archives of Dermatology*, 138(10), pp. 1349-1352. Available at: https://www.researchgate.net/publication/287371621_Efficacy_of_Melaleuca_alternifolia_Essential_Oil_in_the_Treatment_of_Facial_Seborrheic_Dermatitis_A_Double-

blind_Randomized_Placebo-Controlled_Clinical_Trial (Accessed: 18 September 2025).

32. Koca, R. et al. (2016). 'Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial'. *Journal of Dermatological Treatment*, 27(4), pp. 315-318. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5006547/ (Accessed: 18 September 2025).

33. Pierard, G.E. et al. (2006). 'Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial'. *Journal of Drugs in Dermatology*, 5(7), pp. 646-650. Available at: https://pubmed.ncbi.nlm.nih.gov/16865870/ (Accessed: 18 September 2025).

34. Peter, R.U. and Richarz-Barthauer, U. (1995). 'Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial'. *British Journal of Dermatology*, 132(3), pp. 441-445. Available at: https://pubmed.ncbi.nlm.nih.gov/7718463/ (Accessed: 18 September 2025).

35. Danby, F.W. et al. (1993). 'A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff'. *Journal of the American Academy of Dermatology*, 29(6), pp. 1008-1012. Available at: https://pubmed.ncbi.nlm.nih.gov/8245236/ (Accessed: 18 September 2025).

36. Chosidow, O. et al. (2008). 'An open, randomized, prospective, comparative study of topical ketoconazole 2% emulsion and ketoconazole 2% shampoo in the treatment of seborrhoeic dermatitis of the scalp'. *Journal of the European Academy of Dermatology and Venereology*, 22(9), pp. 1113-1118. Available at: https://pubmed.ncbi.nlm.nih.gov/18677657/ (Accessed: 18 September 2025).

37. Ratnavel, R.C. and Squire, R.A. (2002). 'Randomized, open-labeled, non-inferiority study between ketoconazole 2% foam and ketoconazole 2% shampoo in the treatment of mild to moderate seborrhoeic dermatitis'. *Journal of Dermatological Treatment*, 13(2), pp. 51-59. Available at: https://pubmed.ncbi.nlm.nih.gov/12673081/ (Accessed: 18 September 2025).

38. Vena, G.A. et al. (2005). 'Treatment and prophylaxis of seborrheic dermatitis of the scalp with ciclopiroxolamine 1.5% shampoo'. *Skinmed*, 4(1), pp. 43-48. Available at: https://pubmed.ncbi.nlm.nih.gov/15655141/ (Accessed: 18 September 2025).

39. Rigopoulos, D. et al. (2003). 'An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis'. *Journal of the European Academy of Dermatology and Venereology*, 17(2), pp. 225-226. Available at: https://pubmed.ncbi.nlm.nih.gov/12833030/ (Accessed: 18 September 2025).

40. Dreno, B. et al. (2003). 'Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study'. *British Journal of Dermatology*, 148(6), pp. 1240-1244. Available at: https://pubmed.ncbi.nlm.nih.gov/12828753/ (Accessed: 18 September 2025).

41. Efalith Multicenter Trial Group (1992). 'A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis'. *Journal of the American Academy of Dermatology*, 26(3 Pt 2), pp. 452-457. Available at: https://pubmed.ncbi.nlm.nih.gov/1532964/ (Accessed: 18 September 2025).

42. Lebwohl, M. et al. (2002). 'A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis'. *Cutis*, 69(6), pp. 457-462. Available at: https://pubmed.ncbi.nlm.nih.gov/12077544/ (Accessed: 18 September 2025).

43. Kaur, I. et al. (2024). 'A New Purpose to Old Arsenal: Exploring the Safety and Efficacy of

a New Regimen Comprising a Combination of Chlorhexidine Gluconate and Cetrimide for Seborrheic Dermatitis Treatment in a Randomized Placebo-Controlled Clinical Trial'. *Indian Journal of Dermatology*, 69(2), pp. 199-199. Available at: https://pubmed.ncbi.nlm.nih.gov/39463503/ (Accessed: 18 September 2025).

44. Cicek, D. et al. (2006). 'Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment'. *Journal of the European Academy of Dermatology and Venereology*, 20(10), pp. 1305-1309. Available at: https://pubmed.ncbi.nlm.nih.gov/17101479/ (Accessed: 18 September 2025).

45. Kastarinen, H. et al. (2019). 'Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp'. *Cochrane Database of Systematic Reviews*, (5). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6483543/ (Accessed: 18 September 2025).

46. Koca, R. et al. (2011). 'ORAL ITRACONAZOLE FOR THE TREATMENT OF SEVERE SEBORRHOEIC DERMATITIS'. *Journal of the Pakistan Association of Dermatologists*, 21(1), pp. 30-34. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3221212/ (Accessed: 18 September 2025).

47. Koca, R. et al. (2008). 'Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study'. *American Journal of Clinical Dermatology*, 9(1), pp. 51-54. Available at: https://pubmed.ncbi.nlm.nih.gov/18669136/ (Accessed: 18 September 2025).

48. Dall'Oglio, F., Nasca, M.R. and Micali, G. (2022). 'An Overview of the Diagnosis and Management of Seborrheic Dermatitis'. *Journal of Clinical Medicine*, 11(15), p. 4503. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9365318/ (Accessed: 18 September 2025).

49. Naldi, L. and Rebora, A. (2000). 'Treatment of Seborrheic Dermatitis'. *American Family*

Physician, 61(9), pp. 2703-2710. Available at: https://www.aafp.org/pubs/afp/issues/2000/0501/p2703.html/1000 (Accessed: 18 September 2025).

50. Silverberg, J.I. et al. (2024). 'Child and Adult Seborrheic Dermatitis: A Narrative Review of the Current Treatment Landscape'. *American Journal of Clinical Dermatology*. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11909311/ (Accessed: 18 September 2025).

51. U.S. Department of Veterans Affairs (2025). 'Seborrheic Dermatitis - Whole Health Library'. Available at: https://www.va.gov/WHOLEHEALTHLIBRARY/tools/seborrheic-dermatitis.asp (Accessed: 18 September 2025).

52. Bawaneh, A. et al. (2024). 'Nutrition, Obesity, and Seborrheic Dermatitis: Systematic Review'. *JMIR Dermatology*, 7, p. e50143. Available at: https://derma.jmir.org/2024/1/e50143 (Accessed: 18 September 2025).